Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Jefferies Assumes Prime Medicine at Buy, Lowers Price Target of $15

Author: Benzinga Newsdesk | May 07, 2024 10:56am

Jefferies analyst Maury Raycroft assumes Prime Medicine (NASDAQ:PRME) with a Buy rating and lowers Price Target of $15.

Posted In: PRME